You are about to leave DOPTELETHCP.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
For US healthcare professionals only
- Important Safety Information
- Prescribing Information
- Patient Information Leaflet
- For Patients
For US healthcare professionals only
ONE PILL, ONE STRENGTH
Help your patients reach their ITP treatment goals.
Titrate on your terms
Start all patients with a dosage strength of 20 mg once daily and dose adjust as needed.1*†
Initial dose regimen for all patients except those taking Moderate or Strong Dual Inducers or Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4.
After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50×109/L has been achieved, and then obtain platelet counts monthly thereafter.
Taken on their terms
Doptelet is the only oral TPO-RA of its kind that your patients can take based on their schedule.1-3
- Patients can take Doptelet with any meal (food required)
- Patients can take Doptelet at home
Set ITP treatment goals from the start
- One goal of chronic ITP treatment is to increase and maintain a stable platelet count
- Additional factors to consider when discussing treatment goals with your patients include the duration of ITP, frequency of bleeding episodes, increased risk factors for thromboembolism, comorbidities, age, medication adherence, support networks, patient preference, cost, and availability
See Dr. Hillary Maitland discuss ease of administration with Doptelet® (avatrombopag)
Dr. Hillary Maitland, MD, MS
Hematologist at UVA Cancer Center
Assistant Professor of Hematology/Oncology, UVA
Visit the video library to view more presentations.
View DiscussionReferences:
- 1. DOPTELET [package insert]. Durham, NC: AkaRx, Inc.
- 2. Promacta [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
- 3. Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.
Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).
Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.
Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.
These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.
For WAC pricing, visit doptelethcp.com/wac-pricing.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
